These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 17503742

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough.
    Lee CH, Kim SO, Byun KS, Moon MS, Kim EO, Yeon JE, Yoo W, Hong SP.
    Gastroenterology; 2006 Apr; 130(4):1144-52. PubMed ID: 16618409
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization.
    Kim HS, Han KH, Ahn SH, Kim EO, Chang HY, Moon MS, Chung HJ, Yoo W, Kim SO, Hong SP.
    Antivir Ther; 2005 Apr; 10(3):441-9. PubMed ID: 15918335
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of dual priming oligonucleotide-based multiplex PCR for detection of HBV YMDD mutants.
    Woo HY, Park H, Kim BI, Jeon WK, Kim YJ.
    Arch Virol; 2008 Apr; 153(11):2019-25. PubMed ID: 18836856
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S, Nishiguchi S.
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [Abstract] [Full Text] [Related]

  • 10. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
    Ben-Ari Z, Daudi N, Klein A, Sulkes J, Papo O, Mor E, Samra Z, Gadba R, Shouval D, Tur-Kaspa R.
    Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
    [Abstract] [Full Text] [Related]

  • 11. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy.
    Lee SH, Kim HS, Byun IS, Jeong SW, Kim SG, Jang JY, Kim YS, Kim BS.
    J Med Virol; 2012 Feb; 84(2):217-22. PubMed ID: 22170540
    [Abstract] [Full Text] [Related]

  • 12. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
    Deal C, Ajana F, Canva V, Mouton Y, Yazdanpanah Y, Wattré P, Bocket L.
    Ann Biol Clin (Paris); 2002 Feb; 60(5):581-8. PubMed ID: 12368144
    [Abstract] [Full Text] [Related]

  • 13. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM, Kazim SN, Khan LA, Raisuddin S, Parvez MK, Guptan RC, Thakur V, Hasnain SE, Sarin SK.
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [Abstract] [Full Text] [Related]

  • 14. [Detection and analysis of the new kind of G743C and G743A point mutation of HBV P gene in hepatitis B virus infected patients resistant to lamivudine].
    Pan XP, Wo JE, Chen Z, Chen F, Liang WF, Liu KZ.
    Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):616-8. PubMed ID: 14572341
    [Abstract] [Full Text] [Related]

  • 15. PCR restriction fragment length polymorphism in detection of YMDD variants of viral polymerase in hepatitis B virus patients treated with lamivudine.
    Yang DH, Liang WF, Xie YJ, Zhao NF, Fan J.
    Hepatobiliary Pancreat Dis Int; 2002 May; 1(2):232-7. PubMed ID: 14612274
    [Abstract] [Full Text] [Related]

  • 16. Application of PCR-LDR-nucleic acid detection strip in detection of YMDD mutation in hepatitis B patients treated with lamivudine.
    Xu G, You Q, Pickerill S, Zhong H, Wang H, Shi J, Luo Y, You P, Kong H, Lu F, Hu L.
    J Med Virol; 2010 Jul; 82(7):1143-9. PubMed ID: 20513076
    [Abstract] [Full Text] [Related]

  • 17. Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine.
    Amini-Bavil-Olyaee S, Hosseini SY, Sabahi F, Alavian SM.
    Int J Infect Dis; 2008 Jan; 12(1):83-7. PubMed ID: 17698384
    [Abstract] [Full Text] [Related]

  • 18. Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B.
    Han KH, Hong SP, Choi SH, Shin SK, Cho SW, Ahn SH, Hahn JS, Kim SO.
    Antivir Ther; 2011 Jan; 16(1):77-87. PubMed ID: 21311111
    [Abstract] [Full Text] [Related]

  • 19. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH, Lu SN, Chen CH, Wang JH, Wu CM, Hung CH, Tseng PL, Hu TH, Changchien CS, Lee CM.
    Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
    [Abstract] [Full Text] [Related]

  • 20. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine.
    Hatakeyama T, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Kawakami Y, Fujimoto Y, Ochi H, Abe H, Maekawa T, Kawakami H, Yatsuji H, Aisaka Y, Kohno H, Aimitsu S, Chayama K.
    Hepatology; 2007 May; 45(5):1179-86. PubMed ID: 17465002
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.